WINTON GROUP Ltd bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 106,852 shares of the company's stock, valued at approximately $1,993,000. WINTON GROUP Ltd owned about 0.07% of Trevi Therapeutics as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of TRVI. BlackRock Inc. purchased a new stake in shares of Trevi Therapeutics during the second quarter valued at approximately $208,041,000. Rubric Capital Management LP grew its stake in Trevi Therapeutics by 88.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company's stock valued at $46,669,000 after purchasing an additional 3,993,325 shares during the period. Vanguard Group Inc. increased its position in shares of Trevi Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,826,986 shares of the company's stock valued at $53,317,000 after purchasing an additional 510,295 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Trevi Therapeutics by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 5,684,592 shares of the company's stock valued at $106,018,000 after purchasing an additional 495,504 shares during the last quarter. Finally, Viking Global Investors LP raised its stake in shares of Trevi Therapeutics by 232.4% during the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company's stock worth $46,929,000 after purchasing an additional 3,585,875 shares during the period. 95.76% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Trevi Therapeutics in a report on Friday, July 17th. BMO Capital Markets assumed coverage on shares of Trevi Therapeutics in a research note on Monday, July 20th. They issued an "outperform" rating and a $36.00 target price on the stock. B. Riley Financial increased their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a "buy" rating in a research report on Monday, July 20th. JonesTrading raised their price target on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Friday, August 14th. Finally, Oppenheimer lifted their price target on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $27.08.
View Our Latest Stock Report on Trevi Therapeutics
Trevi Therapeutics Stock Down 0.1%
NASDAQ TRVI opened at $15.90 on Friday. The company has a market cap of $2.27 billion, a PE ratio of -46.76 and a beta of 1.04. Trevi Therapeutics, Inc. has a 52 week low of $7.64 and a 52 week high of $20.22. The firm's 50-day simple moving average is $17.80 and its two-hundred day simple moving average is $15.19.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). As a group, equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.48 EPS for the current year.
About Trevi Therapeutics
(
Free Report)
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company's lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.
Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.
Further Reading
Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
